BiomX (NYSEAMERICAN:PHGE) Director Reuven Yeganeh Sells 530,000 Shares

BiomX Inc. (NYSEAMERICAN:PHGE) Director Reuven Yeganeh sold 530,000 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $5.00, for a total value of $2,650,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Reuven Yeganeh also recently made the following trade(s):

• On Monday, March 16th, Reuven Yeganeh sold 450,000 shares of BiomX stock. The stock was sold at an average price of $5.00, for a total value of $2,250,000.00.

BiomX Stock Down 3.6%

NYSEAMERICAN:PHGE traded down $0.19 on Wednesday, reaching $5.04. The company’s stock had a trading volume of 52,934 shares, compared to its average volume of 1,183,020. BiomX Inc. has a 12-month low of $1.50 and a 12-month high of $14.71. The stock has a 50 day moving average price of $4.86 and a 200 day moving average price of $6.36. The firm has a market cap of $8.01 million, a price-to-earnings ratio of -0.20 and a beta of 1.68.

BiomX (NYSEAMERICAN:PHGE) last released its quarterly earnings results on Thursday, February 19th. The company reported $6.99 earnings per share for the quarter. Equities research analysts expect that BiomX Inc. will post -2.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BiomX stock. Alyeska Investment Group L.P. acquired a new stake in BiomX Inc. (NYSEAMERICAN:PHGE) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned approximately 5.99% of BiomX at the end of the most recent quarter. Hedge funds and other institutional investors own 40.57% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright cut shares of BiomX from a “buy” rating to a “hold” rating in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $26.00.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.